Leflunomide对实验性IgA肾病大鼠肾脏病理及MCP-1表达的影响

目的观察leflunomide对实验性IgA肾病(IgA nephropathy IgA N)大鼠肾脏病理及肾组织单核细胞趋化因子(monocyte chemoattractive peptide1,MCP-1)表达的影响,了解其作用机制.方法建立IgAN大鼠模型,随机分成leflunomide组,强的松组,模型对照组,并同时设立正常对照组.行免疫荧光、光镜检查,并用免疫组化和RT-PCR方法分别检测肾组织MCP-1蛋白和基因水平的表达.结果与模型对照组相比,leflunomide组免疫复合物在肾脏的沉积明显减少,系膜区基质增生程度显著减轻(P＜0.01);Leflunomide在基因和蛋白水平均能够有效抑制MCP-1在肾组织的表达(P＜0.05).结论Leflunomide能够减少免疫复合物在肾脏的沉积,减轻系膜区基质增生,并且下调MCP-1在肾脏的表达,减少局部炎症反应,减轻肾脏损害,保护肾脏.

Effects of leflunomide on renal pathology and expression of MCP-1 in renal tissue in rat experimental IgA nephropathy model

Objective] To observe the effects of leflunomide on renal pathology and expression of monocyte chemoattractive peptide1(MCP-1)in rat experimental IgA nephropathy model renal tissue at level of gene and protein,which can help to understand mechanism of action.Methods] Firstly,we constructed IgA nephropathy model,then divided models into leflunomide group,prednisone group,model control group,as well as normal control group.We performed immunofluorescence,light microscope and expression of MCP-1 at the level of gene and protein in renal tissue by immunohistochemistry and RT-PCR methods.Results] Compared with model control,leflunomide lessened the deposit of immunocomplex in renal tissue,diminished the hyperplasia of mesangial matrix(P <0.01);leflunomide could inhibit the expression of MCP-1 at the level of gene and protein in renal tissue(P <0.05).Conclusion] leflunomide can decrease the deposition of immunocomplex,relieve the hyperplasia of mesangial matrix and downregulate the expression of MCP-1 in kidney,diminish local inflammatory reaction,relieve renal loss and protect renal function.